Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.63 |
| ▸ | FNTA | P49354 | 12/20 | 0.58 |
| ▸ | FNTB | P49356 | 12/20 | 0.58 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500901 | 0.92 | FNTA (0.70) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL6171435 | 0.88 | FNTA (0.71) | CYP3A4FNTAFNTB | |
| SCHEMBL7818419 | 0.87 | FNTA (0.77) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL3498572 | 0.84 | CYP3A4 (0.57) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL3500838 | 0.84 | FNTA (0.69) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL14563791 | 0.84 | CYP3A4 (0.56) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL4297497 | 0.84 | CYP3A4 (0.74) | CYP3A4FNTAFNTBPGGT1B | |
| SCHEMBL6170815 | 0.83 | CYP3A4 (0.48) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL23633189 | 0.83 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B | |
| Tipifarnib SCHEMBL21544535 | 0.83 | FNTA (0.80) | CYP3A4FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1150973-B1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PROD INC (US) | 2005-06-15 | — | — | EP | claimed |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. | 2002-08-29 | — | — | US | claimed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | claimed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | claimed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | claimed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | claimed |
| EP-2545919-A1 | Treatment of synucleinopathies | Link Medicine Corporation (US) | 2013-01-16 | — | — | EP | disclosed |
| US-8232402-B2 | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications | LINK MEDICINE CORPORATION (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | LINK MEDICINE CORPORATION (US) | 2011-12-01 | — | — | US | disclosed |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | LINK MEDICINE CORPORATION (MA) | 2010-07-22 | — | — | US | disclosed |
| EP-2155197-A2 | TREATMENT OF LYSOSOMAL STORAGE DISEASES | Link Medicine Corporation (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| WO-2008137692-A1 | TREATMENT OF SYNUCLEINOPATHIES | LINK MEDICINE CORPORATION (US) | 2008-11-13 | — | — | WO | disclosed |
| US-6710209-B2 | INHIBITING FARNESYL PROTEIN TRANSFERASE. | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | PFIZER INC. | 2002-08-29 | — | — | US | disclosed |
| US-6388092-B2 | ANTITUMOR AGENT | PFIZER INC | 2002-05-14 | — | — | US | disclosed |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | YANG BINGWEI V (US) | 2002-02-14 | — | — | US | disclosed |
| EP-1150973-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6258824-B1 | TREATMENT OF HYPERPROLIFERATIVE DISEASES, SUCH AS CANCERS, IN MAMMALS. THIS INVENTION ALSO RELATES TO A PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH COMPOUNDS. | PFIZER INC. | 2001-07-10 | — | — | US | disclosed |
| WO-2000047574-A1 | HETEROARYL-SUBSTITUTED QUINOLIN-2-ONE DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253655-A1 | QUINOLINONE FARNESYL TRANSFERASE INHIBITORS FOR THE TREATMENT OF SYNUCLEINOPATHIES AND OTHER INDICATIONS | PANK1, PANK3, PANK2 | CYP3A4 3795/4885FNTA 4/4885FNTB 19/4885 |
| US-20020120145-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | CYP3A4 721/4885FNTA 855/4885FNTB 2166/4885 |
| US-20020019530-A1 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | NRAS, CCNA1, KRAS | CYP3A4 721/4885FNTA 855/4885FNTB 2166/4885 |
| US-20100184803-A1 | Treatment of Lysosomal Storage Diseases | GAA, GBA1, MAN2B1 | CYP3A4 2825/4885FNTA 19/4885FNTB 24/4885 |
| US-20110294794-A1 | TREATMENT OF PROTEINOPATHIES USING A FARNESYL TRANSFERASE INHIBITOR | FNTA, FNTB, BDNF | CYP3A4 2800/4885FNTA 1/4885FNTB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.